Marlena Walls
Drug Discovery Laboratory (Norway)(NO)
Publications by Year
Research Areas
Lung Cancer Research Studies, PI3K/AKT/mTOR signaling in cancer, MicroRNA in disease regulation, Lung Cancer Treatments and Mutations, Computational Drug Discovery Methods
Most-Cited Works
- → Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design(2010)194 cited
- → Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants(2016)93 cited
- → Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design(2012)79 cited
- → Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity(2011)39 cited
- → Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216(2013)34 cited
- → Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth(2017)21 cited
- → Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors(2009)20 cited
- → RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells(2010)20 cited
- → Abstract 827: Anti-tumor efficacy of BA3011, a novel Conditionally Active Biologic (CAB) anti-AXL-ADC(2018)18 cited
- → Abstract 833: Anti-tumor efficacy of BA3021, a novel Conditionally Active Biologic (CAB) anti-ROR2 ADC(2018)17 cited